Related Experiment Video
Updated: Jul 14, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
[Antagonistic effect of 3'-daidzein sulfonate sodium on prostatic hyperplasia in mice]
Yu-shan Huang1, Jing Zeng, Yu-ping Huang
1Department of Pathophysiology, Huaxi School of Preclinical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, China.
Objective:
To study the antagonistic effect of 3'-daidzein sulfonate sodium (DSS) on benign prostatic hyperplasia (BPH) and its possible mechanism.
Methods:
Forty healthy mice were randomly divided into five groups: a normal control group without any treatment, a model group of BPH treated by subcutaneous injection of testosterone propionate, a positive control group with the BPH procedure treated by Qianliekang, a 20 mg/(kg x d) DSS group with the BPH procedure and a 40 mg/(kg x d) DSS group with the BPH procedure. After 12 days of the above treatments, the mice were sacrificed for measurement of the prostate glandular wet weight, the index of prostate gland (PI), the morphological changes of prostate gland by light microscopy and the contents of testosterone and estradiol in the serum.
Results:
The prostate wet weight and PI decreased dose-dependently after DSS treatment for 12 days compared with the BPH model group (P < 0.05 or P < 0.01). The hyperplastic epithelioglandular papilla waned and even disappeared in the DSS treated groups under the light microscope, the epithelial cells became cubical or flat. The effect of DSS at 40 mg/(kg x d) was similar to that of the positive anti-BPH drug Qianliekang. DSS reduced the serum testosterone, estradiol contents and the T/E2 ratio (P < 0.05 or P < 0.01).
Conclusion:
DSS has significant antagonistic effect on BPH induced by testosterone propionate in mice, which may involve its regulatory action on the sex hormone balance.
Insights
3'-daidzein sulfonate sodium (DSS) effectively reduces prostate size and improves BPH symptoms in mice. This compound may help rebalance sex hormones, offering a potential new treatment for benign prostatic hyperplasia.
Area of Science:
- Endocrinology
- Pharmacology
- Urology
Context:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- Testosterone propionate is used to induce BPH in animal models.
- Hormonal imbalances play a key role in BPH development.
Purpose:
- To investigate the therapeutic potential of 3 '-daidzein sulfonate sodium (DSS) against experimentally induced BPH.
- To elucidate the underlying mechanisms of DSS action in BPH.
- To compare the efficacy of DSS with a standard anti-BPH medication.
Summary:
- Mice with testosterone-induced BPH were treated with varying doses of DSS or Qianliekang.
- DSS treatment led to a dose-dependent reduction in prostate weight and prostate index.
- Histological examination revealed decreased epithelial hyperplasia, and serum analysis showed modulation of testosterone and estradiol levels.
Impact:
- DSS demonstrates significant anti-BPH effects in a mouse model.
- The findings suggest DSS may regulate sex hormone balance, offering a novel therapeutic strategy.
- This research provides a basis for further investigation of DSS in BPH treatment.